JP2021500349A5 - - Google Patents

Download PDF

Info

Publication number
JP2021500349A5
JP2021500349A5 JP2020522016A JP2020522016A JP2021500349A5 JP 2021500349 A5 JP2021500349 A5 JP 2021500349A5 JP 2020522016 A JP2020522016 A JP 2020522016A JP 2020522016 A JP2020522016 A JP 2020522016A JP 2021500349 A5 JP2021500349 A5 JP 2021500349A5
Authority
JP
Japan
Prior art keywords
antibody
composition
composition according
dose
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020522016A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500349A (ja
JP7308191B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/056441 external-priority patent/WO2019079548A1/en
Publication of JP2021500349A publication Critical patent/JP2021500349A/ja
Publication of JP2021500349A5 publication Critical patent/JP2021500349A5/ja
Priority to JP2022186406A priority Critical patent/JP2023018062A/ja
Application granted granted Critical
Publication of JP7308191B2 publication Critical patent/JP7308191B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020522016A 2017-10-18 2018-10-18 抗cd47剤ベースの卵巣癌療法 Active JP7308191B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022186406A JP2023018062A (ja) 2017-10-18 2022-11-22 抗cd47剤ベースの卵巣癌療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762573835P 2017-10-18 2017-10-18
US62/573,835 2017-10-18
PCT/US2018/056441 WO2019079548A1 (en) 2017-10-18 2018-10-18 OVARIAN CANCER THERAPY BASED ON ANTI-CD47 AGENT

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022186406A Division JP2023018062A (ja) 2017-10-18 2022-11-22 抗cd47剤ベースの卵巣癌療法

Publications (3)

Publication Number Publication Date
JP2021500349A JP2021500349A (ja) 2021-01-07
JP2021500349A5 true JP2021500349A5 (cg-RX-API-DMAC7.html) 2021-10-07
JP7308191B2 JP7308191B2 (ja) 2023-07-13

Family

ID=64267915

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020522016A Active JP7308191B2 (ja) 2017-10-18 2018-10-18 抗cd47剤ベースの卵巣癌療法
JP2022186406A Pending JP2023018062A (ja) 2017-10-18 2022-11-22 抗cd47剤ベースの卵巣癌療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022186406A Pending JP2023018062A (ja) 2017-10-18 2022-11-22 抗cd47剤ベースの卵巣癌療法

Country Status (12)

Country Link
US (2) US11802153B2 (cg-RX-API-DMAC7.html)
EP (2) EP3697817B1 (cg-RX-API-DMAC7.html)
JP (2) JP7308191B2 (cg-RX-API-DMAC7.html)
KR (1) KR102776457B1 (cg-RX-API-DMAC7.html)
CN (2) CN111247172B (cg-RX-API-DMAC7.html)
AU (1) AU2018351006B2 (cg-RX-API-DMAC7.html)
CA (1) CA3078253A1 (cg-RX-API-DMAC7.html)
ES (2) ES2989007T3 (cg-RX-API-DMAC7.html)
PL (2) PL4177270T3 (cg-RX-API-DMAC7.html)
PT (2) PT4177270T (cg-RX-API-DMAC7.html)
SI (2) SI4177270T1 (cg-RX-API-DMAC7.html)
WO (1) WO2019079548A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3011097C (en) 2016-01-11 2022-12-20 Forty Seven, Inc. Humanized, mouse or chimeric anti-cd47 monoclonal antibodies
PL4177270T3 (pl) 2017-10-18 2024-11-18 Forty Seven, Inc. Terapia nowotworu złośliwego jajnika w oparciu o środek anty-cd47
EP3752190B1 (en) 2018-02-12 2022-07-06 Forty Seven, Inc. Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies
EP3846855B1 (en) * 2018-09-04 2024-12-04 Pfizer Inc. Cd47 blockade with parp inhibition for disease treatment
JP7369297B2 (ja) 2019-12-17 2023-10-25 ファイザー・インク Cd47、pd-l1に特異的な抗体、およびその使用
US20230081265A1 (en) * 2020-04-06 2023-03-16 The Board Of Trustees Of The Leland Stanford Junior University Antibody formulation
EP4168449A1 (en) * 2020-06-22 2023-04-26 MorphoSys AG Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpa-cd47 innate immune checkpoint
CN117222413A (zh) * 2021-02-10 2023-12-12 同润生物医药(上海)有限公司 治疗肿瘤的方法和组合
WO2022218384A1 (zh) * 2021-04-14 2022-10-20 中山康方生物医药有限公司 抗cd47的单克隆抗体及其用途
EP4353265A4 (en) * 2021-06-10 2024-10-02 ONO Pharmaceutical Co., Ltd. METHOD OF TREATING CANCER BY MEANS OF A COMBINATION OF A CD47 INHIBITOR, AN IMMUNE CHECKPOINT INHIBITOR AND STANDARD THERAPY
CN115245516A (zh) * 2021-12-31 2022-10-28 郑州大学第一附属医院 一种抗卵巢癌肿瘤药物联用方法、体外和体内验证方法
WO2023172643A1 (en) * 2022-03-08 2023-09-14 Whitehead Institute For Biomedical Research The combination of macrophage-directed immunotherapy and targeted agents for treatment of cancer
TWI876305B (zh) * 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
US20230391868A1 (en) * 2022-06-02 2023-12-07 The George Washington University Compositions for and methods of treating cancer

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3056515T (pt) 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação da fagocitose mediada por cd47
SI2477648T1 (sl) 2009-09-15 2022-09-30 The Board Of Trustees Of The Leland Stanford Junior University Sinergijska terapija proti CD47 za krvne rake
WO2011041453A1 (en) 2009-09-29 2011-04-07 The Board Of Trustees Of The Leland Stanford Junior University Isolation and use of melanoma cancer stem cells
SG10201401123VA (en) * 2010-02-23 2014-08-28 Genentech Inc Anti-Angiogenesis Therapy For The Treatment Of Ovarian Cancer
AU2011252851B2 (en) 2010-05-14 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to CD47
WO2012088309A1 (en) 2010-12-21 2012-06-28 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic and diagnostic methods for manipulating phagocytosis through calreticulin and low density lipoprotein-related receptor
EP3766511A1 (en) 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
MX2015007446A (es) 2012-12-12 2015-12-07 Vasculox Inc Anticuerpos terapeuticos para cd47.
CN105189556A (zh) 2013-03-15 2015-12-23 小利兰·斯坦福大学托管委员会 用于实现治疗有效剂量的抗cd47剂的方法
WO2014179132A1 (en) 2013-04-29 2014-11-06 The Board Of Trustees Of The Leland Stanford Junior University Use of anti-cd47 agents to enhance immunization
US9945870B2 (en) 2013-05-17 2018-04-17 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-CD47 agent
WO2015138600A2 (en) 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
EP3177640B1 (en) 2014-08-08 2020-05-06 The Board of Trustees of the Leland Stanford Junior University High affinity pd-1 agents and methods of use
WO2016023001A1 (en) 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
PL3204018T3 (pl) 2014-10-07 2022-01-03 Immunomedics, Inc. Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek
WO2016065329A1 (en) 2014-10-24 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗pd-1抗體類和使用彼等之方法
EP3247464B1 (en) 2015-01-21 2019-09-18 The Board of Trustees of the Leland Stanford Junior University Use of tlr agonist and anti-cd47 agent to enhance phagocytosis of cancer cells
WO2016179399A1 (en) 2015-05-06 2016-11-10 The Board Of Trustees Of The Leland Stanford Junior University High affinity cd47 analogs
US20180147257A1 (en) 2015-05-22 2018-05-31 The Board Of Trustees Of The Leland Stanford Junior University Btn3a ectodomain proteins and methods of use
WO2017019767A1 (en) 2015-07-27 2017-02-02 Myosotis, Llc Inhibition of CXCL12 in Cancer Immunotherapy
ES2894335T5 (es) 2015-08-26 2024-06-27 Univ Leland Stanford Junior Reducción mejorada de células objetivo con bloqueo de CD47 y un agonista coestimulador inmune
CN116425875A (zh) * 2015-09-18 2023-07-14 安驰肿瘤公司 治疗性cd47抗体
KR102988978B1 (ko) * 2015-12-11 2026-07-10 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Cd47 및 egfr의 이중 표적화를 이용한 암의 치료
WO2017117196A1 (en) 2015-12-28 2017-07-06 Syndax Pharmaceuticals, Inc. Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer
CA3011097C (en) 2016-01-11 2022-12-20 Forty Seven, Inc. Humanized, mouse or chimeric anti-cd47 monoclonal antibodies
AU2017210224B2 (en) 2016-01-21 2024-02-08 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with combinations of immunoregulatory agents
KR20240016445A (ko) 2016-04-15 2024-02-06 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법
EP3493845A4 (en) 2016-08-03 2020-04-15 The Board of Trustees of the Leland Stanford Junior University INTERRUPTION OF FC RECEPTOR USE ON MACROPHAGES TO IMPROVE THE EFFECTIVENESS OF ANTI-SIRPALPHA ANTIBODY THERAPY
WO2018031419A1 (en) 2016-08-12 2018-02-15 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for enhancing immunogenic cross-presentation of tumor antigens
EP3532497B1 (en) 2016-10-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
WO2018165015A1 (en) 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
EP4194470A1 (en) 2017-10-18 2023-06-14 Forty Seven, Inc. Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
PL4177270T3 (pl) 2017-10-18 2024-11-18 Forty Seven, Inc. Terapia nowotworu złośliwego jajnika w oparciu o środek anty-cd47
WO2019241403A1 (en) 2018-06-13 2019-12-19 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis
US20220091104A1 (en) 2018-09-28 2022-03-24 The Board Of Trustees Of The Leland Stanford Junior University Analysis of polymorphisms in sirp-alpha for evaluating response to immunotherapy
WO2020160285A1 (en) 2019-02-01 2020-08-06 The Board Of Trustees Of The Leland Stanford Junior University SIRPα EXPRESSION ON T CELLS IS A BIOMARKER FOR FUNCTIONAL T CELLS DURING EXHAUSTION
WO2020163692A1 (en) 2019-02-08 2020-08-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway

Similar Documents

Publication Publication Date Title
Brosnan et al. Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies
EP2903610B1 (en) Cancer treatments
Pinto et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)
CN102223897B (zh) 抗-vegf抗体与化学治疗联合用于治疗乳腺癌的应用
Macaulay et al. Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors
JP2020059713A (ja) 膠芽腫治療のための併用療法
EP3697817B1 (en) Anti-cd47 agent-based ovarian cancer therapy
Pandey et al. Engineered nanomaterials as an effective tool for HER2+ breast cancer therapy
AU2017204320A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
TW200838875A (en) Combination therapy with angiogenesis inhibitors
EP3446709A1 (en) Combination therapy for the treatment of glioblastoma
JP2021500336A5 (cg-RX-API-DMAC7.html)
EP3553083A1 (en) Combination therapy for the treatment of ovarian cancer
JP2020506945A (ja) がんの治療のための方法、組成物及びキット
Koukourakis et al. Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer
KR20210084560A (ko) Pd-1/pd-l1 신호전달 억제제에 반응하지 않는 암을 치료하기 위한 방법 및 약제
EP1740182A2 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
WO2012106379A1 (en) Sensitization of cancer cells to treatment
Miyata et al. Current treatment landscape for patients with non–small cell lung cancer with common EGFR mutations
TW201109032A (en) Anti-angiogenesis therapy for the treatment of previously treated breast cancer
JP2005511663A5 (cg-RX-API-DMAC7.html)
George et al. Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours
US20210363253A1 (en) Use of combined treatment of pd-1 antibody and apatinib for treating triple negative breast cancer
RU2774721C2 (ru) Применение комбинированного лечения на основе антитела к PD-1 и апатиниба для лечения трижды негативного рака молочной железы
Von Hoff Horizons for Cancer Chemotherapy (and Nonchemotherapy)